The use of dosimetry in the treatment of differentiated thyroid cancer.

M Lassmann, H Hänscheid, FA Verburg… - The Quarterly Journal …, 2011 - europepmc.org
The standard treatment for the ablation of thyroid remnant tissue following surgery as well as
for the treatment of iodine avid metastases in patients suffering from differentiated thyroid …

Advantages of dosimetry in 131I therapy of differentiated thyroid carcinoma.

FA Verburg - The Quarterly Journal of Nuclear Medicine and …, 2019 - europepmc.org
For advanced differentiated thyroid carcinoma (DTC) several iodine-131 (131I) activity
selection strategies are available. The most common approach empirical activity selection …

Individualized dosimetry in the management of metastatic differentiated thyroid cancer

C Chiesa, MR Castellani, C Vellani… - … Quarterly Journal of …, 2009 - search.proquest.com
This paper analyzes the available data on the dosimetric approach and describes the use of
dosimetry in the Division of Nuclear Medicine of the National Cancer Institute in Milan …

Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma

M Salvatori, M Luster - European journal of nuclear medicine and …, 2010 - Springer
Traditionally, nuclear medicine has been regarded mainly as a diagnostic specialty in which
the administration of radioactive substances yields information whose importance far …

Physics aspects of setting up a multicenter clinical trial involving internal dosimetry of radioiodine treatment of differentiated thyroid cancer.

J Taprogge, F Leek, GD Flux - … of the Italian Association of Nuclear …, 2019 - europepmc.org
The field of molecular radiotherapy is expanding rapidly, with the advent of many new
radiotherapeutics for the treatment of common as well as for rare cancers. Treatment …

Personalized dosimetry in the context of radioiodine therapy for differentiated thyroid cancer

M Pacilio, M Conte, V Frantellizzi, MS De Feo… - Diagnostics, 2022 - mdpi.com
The most frequent thyroid cancer is Differentiated Thyroid Cancer (DTC) representing more
than 95% of cases. A suitable choice for the treatment of DTC is the systemic administration …

Dosimetry in the therapy of metastatic differentiated thyroid cancer administering high 131I activity: the experience of Busto Arsizio Hospital (Italy).

L Bianchi, A Baroli, G Lomuscio… - The Quarterly Journal …, 2012 - europepmc.org
Aim The purpose of the present work was to evaluate the impact of 131I high activity therapy
treatments of metastatic differentiated thyroid cancer (MDTC) in terms of feasibility …

Clinical radionuclide therapy dosimetry: the quest for the “Holy Gray”

B Brans, L Bodei, F Giammarile, O Lindén… - European journal of …, 2007 - Springer
Introduction Radionuclide therapy has distinct similarities to, but also profound differences
from external radiotherapy. Review This review discusses techniques and results of …

Pre-therapeutic blood dosimetry in patients with differentiated thyroid carcinoma using 124-iodine: predicted blood doses correlate with changes in blood cell counts …

V Hartung-Knemeyer, J Nagarajah, W Jentzen… - Annals of nuclear …, 2012 - Springer
Objective Pre-therapeutic blood dosimetry prior to a high-dose radioiodine therapy (RAIT) is
recommended and a blood dose of 2 Gy is considered to be safe. In this study, changes in …

Indirect assessment of the maximum empirical activity (250 mCi) with respect to dosimetry concepts in radioiodine therapy of metastatic differentiated thyroid cancer

M Abuqbeitah, M Demir, L Kabasakal… - Nuclear Medicine …, 2018 - journals.lww.com
Aim The development of reliable dosimetry models promotes the individualized therapy
concept toward more success and less complications. This paper evaluates the traditional …